TY - JOUR AU - Zinman, B. AU - Wanner, C. AU - Lachin, J. M. AU - Fitchett, D. AU - Bluhmki, E. AU - Hantel, S. AU - Mattheus, M. AU - Devins, T. AU - Johansen, O. E. AU - Woerle, H. J. PY - 2015 DA - 2015// TI - Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1504720 DO - 10.1056/NEJMoa1504720 ID - Zinman2015 ER - TY - JOUR AU - Marso, S. P. AU - Daniels, G. H. AU - Brown-Frandsen, K. AU - Kristensen, P. AU - Mann, J. F. AU - Nauck, M. A. AU - Nissen, S. E. AU - Pocock, S. AU - Poulter, N. R. AU - Ravn, L. S. PY - 2016 DA - 2016// TI - Liraglutide and cardiovascular outcomes in type 2 diabetes JO - N Engl J Med VL - 375 UR - https://doi.org/10.1056/NEJMoa1603827 DO - 10.1056/NEJMoa1603827 ID - Marso2016 ER - TY - JOUR AU - Marso, S. P. AU - Bain, S. C. AU - Consoli, A. AU - Eliaschewitz, F. G. AU - Jodar, E. AU - Leiter, L. A. AU - Lingvay, I. AU - Rosenstock, J. AU - Seufert, J. AU - Warren, M. L. PY - 2016 DA - 2016// TI - Semaglutide and cardiovascular outcomes in patients with type 2 diabetes JO - N Engl J Med VL - 375 UR - https://doi.org/10.1056/NEJMoa1607141 DO - 10.1056/NEJMoa1607141 ID - Marso2016 ER - TY - JOUR AU - Neal, B. AU - Perkovic, V. AU - Mahaffey, K. W. AU - Zeeuw, D. AU - Fulcher, G. AU - Erondu, N. AU - Shaw, W. AU - Law, G. AU - Desai, M. AU - Matthews, D. R. PY - 2017 DA - 2017// TI - Canagliflozin and cardiovascular and renal events in type 2 diabetes JO - N Engl J Med VL - 377 UR - https://doi.org/10.1056/NEJMoa1611925 DO - 10.1056/NEJMoa1611925 ID - Neal2017 ER - TY - JOUR PY - 2018 DA - 2018// TI - 8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2018 JO - Diabetes care VL - 41 UR - https://doi.org/10.2337/dc18-S008 DO - 10.2337/dc18-S008 ID - ref5 ER - TY - JOUR PY - 2018 DA - 2018// TI - 9. Cardiovascular disease and risk management: standards of medical care in diabetes-2018 JO - Diabetes care VL - 41 UR - https://doi.org/10.2337/dc18-S009 DO - 10.2337/dc18-S009 ID - ref6 ER - TY - JOUR AU - Holst, J. J. PY - 2007 DA - 2007// TI - The physiology of glucagon-like peptide 1 JO - Physiol Rev VL - 87 UR - https://doi.org/10.1152/physrev.00034.2006 DO - 10.1152/physrev.00034.2006 ID - Holst2007 ER - TY - JOUR AU - Holst, J. J. AU - Vilsboll, T. AU - Deacon, C. F. PY - 2009 DA - 2009// TI - The incretin system and its role in type 2 diabetes mellitus JO - Mol Cell Endocrinol VL - 297 UR - https://doi.org/10.1016/j.mce.2008.08.012 DO - 10.1016/j.mce.2008.08.012 ID - Holst2009 ER - TY - JOUR AU - Davidson, M. H. PY - 2011 DA - 2011// TI - Cardiovascular effects of glucagonlike peptide-1 agonists JO - Am J Cardiol VL - 108 UR - https://doi.org/10.1016/j.amjcard.2011.03.046 DO - 10.1016/j.amjcard.2011.03.046 ID - Davidson2011 ER - TY - JOUR AU - Nauck, M. A. AU - Meier, J. J. AU - Cavender, M. A. AU - Abd El, M. A. AU - Drucker, D. J. PY - 2017 DA - 2017// TI - Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors JO - Circulation VL - 136 UR - https://doi.org/10.1161/CIRCULATIONAHA.117.028136 DO - 10.1161/CIRCULATIONAHA.117.028136 ID - Nauck2017 ER - TY - JOUR AU - Lim, S. AU - Kim, K. M. AU - Nauck, M. A. PY - 2018 DA - 2018// TI - Glucagon-like peptide-1 receptor agonists and cardiovascular events: class effects versus individual patterns JO - Trends Endocrinol Metab TEM VL - 29 UR - https://doi.org/10.1016/j.tem.2018.01.011 DO - 10.1016/j.tem.2018.01.011 ID - Lim2018 ER - TY - JOUR AU - Htike, Z. Z. AU - Zaccardi, F. AU - Papamargaritis, D. AU - Webb, D. R. AU - Khunti, K. AU - Davies, M. J. PY - 2017 DA - 2017// TI - Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis JO - Diabetes Obes Metab VL - 19 UR - https://doi.org/10.1111/dom.12849 DO - 10.1111/dom.12849 ID - Htike2017 ER - TY - JOUR AU - Mazidi, M. AU - Rezaie, P. AU - Gao, H. K. AU - Kengne, A. P. PY - 2017 DA - 2017// TI - Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients JO - J Am Heart Assoc VL - 6 UR - https://doi.org/10.1161/JAHA.116.004007 DO - 10.1161/JAHA.116.004007 ID - Mazidi2017 ER - TY - JOUR AU - Bolinder, J. AU - Ljunggren, O. AU - Johansson, L. AU - Wilding, J. AU - Langkilde, A. M. AU - Sjostrom, C. D. AU - Sugg, J. AU - Parikh, S. PY - 2014 DA - 2014// TI - Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin JO - Diabetes Obes Metab VL - 16 UR - https://doi.org/10.1111/dom.12189 DO - 10.1111/dom.12189 ID - Bolinder2014 ER - TY - JOUR AU - Sha, S. AU - Polidori, D. AU - Heise, T. AU - Natarajan, J. AU - Farrell, K. AU - Wang, S. S. AU - Sica, D. AU - Rothenberg, P. AU - Plum-Morschel, L. PY - 2014 DA - 2014// TI - Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus JO - Diabetes Obes Metab VL - 16 UR - https://doi.org/10.1111/dom.12322 DO - 10.1111/dom.12322 ID - Sha2014 ER - TY - JOUR AU - Secher, A. AU - Jelsing, J. AU - Baquero, A. F. AU - Hecksher-Sorensen, J. AU - Cowley, M. A. AU - Dalboge, L. S. AU - Hansen, G. AU - Grove, K. L. AU - Pyke, C. AU - Raun, K. PY - 2014 DA - 2014// TI - The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss JO - J Clin Investig VL - 124 UR - https://doi.org/10.1172/JCI75276 DO - 10.1172/JCI75276 ID - Secher2014 ER - TY - JOUR AU - Knudsen, L. B. AU - Secher, A. AU - Hecksher-Sorensen, J. AU - Pyke, C. PY - 2016 DA - 2016// TI - Long-acting glucagon-like peptide-1 receptor agonists have direct access to and effects on pro-opiomelanocortin/cocaine- and amphetamine-stimulated transcript neurons in the mouse hypothalamus JO - J Diabetes Invest VL - 7 UR - https://doi.org/10.1111/jdi.12463 DO - 10.1111/jdi.12463 ID - Knudsen2016 ER - TY - JOUR AU - Lau, J. AU - Bloch, P. AU - Schaffer, L. AU - Pettersson, I. AU - Spetzler, J. AU - Kofoed, J. AU - Madsen, K. AU - Knudsen, L. B. AU - McGuire, J. AU - Steensgaard, D. B. PY - 2015 DA - 2015// TI - Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide JO - J Med Chem VL - 58 UR - https://doi.org/10.1021/acs.jmedchem.5b00726 DO - 10.1021/acs.jmedchem.5b00726 ID - Lau2015 ER - TY - JOUR AU - Koska, J. AU - Sands, M. AU - Burciu, C. AU - D’Souza, K. M. AU - Raravikar, K. AU - Liu, J. AU - Truran, S. AU - Franco, D. A. AU - Schwartz, E. A. AU - Schwenke, D. C. PY - 2015 DA - 2015// TI - Exenatide protects against glucose- and lipid-induced endothelial dysfunction: evidence for direct vasodilation effect of GLP-1 receptor agonists in humans JO - Diabetes VL - 64 UR - https://doi.org/10.2337/db14-0976 DO - 10.2337/db14-0976 ID - Koska2015 ER - TY - JOUR AU - Lambadiari, V. AU - Pavlidis, G. AU - Kousathana, F. AU - Varoudi, M. AU - Vlastos, D. AU - Maratou, E. AU - Georgiou, D. AU - Andreadou, I. AU - Parissis, J. AU - Triantafyllidi, H. PY - 2018 DA - 2018// TI - Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes JO - Cardiovasc Diabetol VL - 17 UR - https://doi.org/10.1186/s12933-017-0646-z DO - 10.1186/s12933-017-0646-z ID - Lambadiari2018 ER - TY - JOUR AU - Kushima, H. AU - Mori, Y. AU - Koshibu, M. AU - Hiromura, M. AU - Kohashi, K. AU - Terasaki, M. AU - Fukui, T. AU - Hirano, T. PY - 2017 DA - 2017// TI - The role of endothelial nitric oxide in the anti-restenotic effects of liraglutide in a mouse model of restenosis JO - Cardiovasc Diabetol VL - 16 UR - https://doi.org/10.1186/s12933-017-0603-x DO - 10.1186/s12933-017-0603-x ID - Kushima2017 ER - TY - JOUR AU - Kaul, S. PY - 2017 DA - 2017// TI - Mitigating cardiovascular risk in type 2 diabetes with antidiabetes drugs: a review of principal cardiovascular outcome results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 trials JO - Diabetes Care VL - 40 UR - https://doi.org/10.2337/dc17-0291 DO - 10.2337/dc17-0291 ID - Kaul2017 ER - TY - JOUR AU - Sattar, N. AU - Petrie, M. C. AU - Zinman, B. AU - Januzzi, J. L. PY - 2017 DA - 2017// TI - Novel diabetes drugs and the cardiovascular specialist JO - J Am Coll Cardiol VL - 69 UR - https://doi.org/10.1016/j.jacc.2017.04.014 DO - 10.1016/j.jacc.2017.04.014 ID - Sattar2017 ER - TY - JOUR AU - Lytvyn, Y. AU - Bjornstad, P. AU - Udell, J. A. AU - Lovshin, J. A. AU - Cherney, D. Z. I. PY - 2017 DA - 2017// TI - Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials JO - Circulation VL - 136 UR - https://doi.org/10.1161/CIRCULATIONAHA.117.030012 DO - 10.1161/CIRCULATIONAHA.117.030012 ID - Lytvyn2017 ER - TY - JOUR AU - Margulies, K. B. AU - Hernandez, A. F. AU - Redfield, M. M. AU - Givertz, M. M. AU - Oliveira, G. H. AU - Cole, R. AU - Mann, D. L. AU - Whellan, D. J. AU - Kiernan, M. S. AU - Felker, G. M. PY - 2016 DA - 2016// TI - Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial JO - JAMA VL - 316 UR - https://doi.org/10.1001/jama.2016.10260 DO - 10.1001/jama.2016.10260 ID - Margulies2016 ER - TY - JOUR AU - Wanner, C. AU - Inzucchi, S. E. AU - Lachin, J. M. AU - Fitchett, D. AU - Eynatten, M. AU - Mattheus, M. AU - Johansen, O. E. AU - Woerle, H. J. AU - Broedl, U. C. AU - Zinman, B. PY - 2016 DA - 2016// TI - Empagliflozin and progression of kidney disease in type 2 diabetes JO - N Engl J Med VL - 375 UR - https://doi.org/10.1056/NEJMoa1515920 DO - 10.1056/NEJMoa1515920 ID - Wanner2016 ER - TY - JOUR AU - Mann, J. F. E. AU - Orsted, D. D. AU - Brown-Frandsen, K. AU - Marso, S. P. AU - Poulter, N. R. AU - Rasmussen, S. AU - Tornoe, K. AU - Zinman, B. AU - Buse, J. B. PY - 2017 DA - 2017// TI - Liraglutide and renal outcomes in type 2 diabetes JO - N Engl J Med VL - 377 UR - https://doi.org/10.1056/NEJMoa1616011 DO - 10.1056/NEJMoa1616011 ID - Mann2017 ER - TY - JOUR AU - Holman, R. R. AU - Bethel, M. A. AU - Mentz, R. J. AU - Thompson, V. P. AU - Lokhnygina, Y. AU - Buse, J. B. AU - Chan, J. C. AU - Choi, J. AU - Gustavson, S. M. AU - Iqbal, N. PY - 2017 DA - 2017// TI - Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes JO - N Engl J Med VL - 377 UR - https://doi.org/10.1056/NEJMoa1612917 DO - 10.1056/NEJMoa1612917 ID - Holman2017 ER - TY - JOUR AU - Pfeffer, M. A. AU - Claggett, B. AU - Diaz, R. AU - Dickstein, K. AU - Gerstein, H. C. AU - Kober, L. V. AU - Lawson, F. C. AU - Ping, L. AU - Wei, X. AU - Lewis, E. F. PY - 2015 DA - 2015// TI - Lixisenatide in patients with type 2 diabetes and acute coronary syndrome JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1509225 DO - 10.1056/NEJMoa1509225 ID - Pfeffer2015 ER - TY - JOUR AU - Mahaffey, K. W. AU - Neal, B. AU - Perkovic, V. AU - Zeeuw, D. AU - Fulcher, G. AU - Erondu, N. AU - Shaw, W. AU - Fabbrini, E. AU - Sun, T. AU - Li, Q. PY - 2018 DA - 2018// TI - Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (canagliflozin cardiovascular assessment study) JO - Circulation VL - 137 UR - https://doi.org/10.1161/CIRCULATIONAHA.117.032038 DO - 10.1161/CIRCULATIONAHA.117.032038 ID - Mahaffey2018 ER - TY - JOUR AU - Green, J. B. AU - Bethel, M. A. AU - Armstrong, P. W. AU - Buse, J. B. AU - Engel, S. S. AU - Garg, J. AU - Josse, R. AU - Kaufman, K. D. AU - Koglin, J. AU - Korn, S. PY - 2015 DA - 2015// TI - Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1501352 DO - 10.1056/NEJMoa1501352 ID - Green2015 ER - TY - JOUR AU - Scirica, B. M. AU - Bhatt, D. L. AU - Braunwald, E. AU - Steg, P. G. AU - Davidson, J. AU - Hirshberg, B. AU - Ohman, P. AU - Frederich, R. AU - Wiviott, S. D. AU - Hoffman, E. B. PY - 2013 DA - 2013// TI - Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus JO - N Engl J Med VL - 369 UR - https://doi.org/10.1056/NEJMoa1307684 DO - 10.1056/NEJMoa1307684 ID - Scirica2013 ER - TY - JOUR AU - White, W. B. AU - Cannon, C. P. AU - Heller, S. R. AU - Nissen, S. E. AU - Bergenstal, R. M. AU - Bakris, G. L. AU - Perez, A. T. AU - Fleck, P. R. AU - Mehta, C. R. AU - Kupfer, S. PY - 2013 DA - 2013// TI - Alogliptin after acute coronary syndrome in patients with type 2 diabetes JO - N Engl J Med VL - 369 UR - https://doi.org/10.1056/NEJMoa1305889 DO - 10.1056/NEJMoa1305889 ID - White2013 ER - TY - JOUR AU - Zhang, Z. AU - Chen, X. AU - Lu, P. AU - Zhang, J. AU - Xu, Y. AU - He, W. AU - Li, M. AU - Zhang, S. AU - Jia, J. AU - Shao, S. PY - 2017 DA - 2017// TI - Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes JO - Cardiovasc Diabetol VL - 16 UR - https://doi.org/10.1186/s12933-017-0512-z DO - 10.1186/s12933-017-0512-z ID - Zhang2017 ER - TY - JOUR AU - Nauck, M. PY - 2016 DA - 2016// TI - Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors JO - Diabetes Obes Metab VL - 18 UR - https://doi.org/10.1111/dom.12591 DO - 10.1111/dom.12591 ID - Nauck2016 ER - TY - JOUR AU - Packer, M. PY - 2018 DA - 2018// TI - Have dipeptidyl peptidase-4 inhibitors ameliorated the vascular complications of type 2 diabetes in large-scale trials? The potential confounding effect of stem-cell chemokines JO - Cardiovasc Diabetol VL - 17 UR - https://doi.org/10.1186/s12933-017-0648-x DO - 10.1186/s12933-017-0648-x ID - Packer2018 ER - TY - JOUR AU - Packer, M. PY - 2018 DA - 2018// TI - Do DPP-4 inhibitors cause heart failure events by promoting adrenergically mediated cardiotoxicity? clues from laboratory models and clinical trials JO - Circ Res VL - 122 UR - https://doi.org/10.1161/CIRCRESAHA.118.312673 DO - 10.1161/CIRCRESAHA.118.312673 ID - Packer2018 ER - TY - JOUR AU - Ishii, H. AU - Madin-Warburton, M. AU - Strizek, A. AU - Thornton-Jones, L. AU - Suzuki, S. PY - 2018 DA - 2018// TI - The cost-effectiveness of dulaglutide versus insulin glargine for the treatment of type 2 diabetes mellitus in Japan JO - J Med Econ VL - 21 UR - https://doi.org/10.1080/13696998.2018.1431918 DO - 10.1080/13696998.2018.1431918 ID - Ishii2018 ER -